Eli Lilly and Company (NYSE:LLY) today announced that data from studies of Verzenio®Â (abemaciclib) and Retevmo®Â (selpercatinib) will be presented at the 2022 European Society for Medical Oncology (ESMO) Congress, to be held September 9-13, 2022.
Presentation Highlights
Verzenio (abemaciclib)
Lilly will present interim overall survival results from the double-blind, randomized Phase 3 MONARCH 3 study of Verzenio in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer as well as final overall survival results from the Phase 2 monarcHER study in HR+, HER2+ advanced breast cancer.
Retevmo (selpercatinib)
Lilly will present longer-term follow-up data for patients with medullary thyroid cancer (MTC) and data on the continuation of Retevmo beyond progression in patients with rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) from the Retevmo LIBRETTO-001 trial.
A list of the presentations, along with their viewing details, is shared below.
Medicine
Abstract Title
Details
Verzenio
(abemaciclib)
MONARCH 3: Interim overall survival
(OS) results of abemaciclib plus a
nonsteroidal aromatase inhibitor (NSAI)
in patients (pts) with HR+, HER2-
advanced breast cancer (ABC)
Abstract #LBA15
Proffered Paper Session: Breast Cancer, Metastatic
Friday, September 9
16:00 – 16:10 CEST
Verzenio
(abemaciclib)
Final overall survival (OS) for
abemaciclib plus trastuzumab +/-
fulvestrant versus trastuzumab plus
chemotherapy in patients with HR+,
HER2+ advanced breast cancer
(monarcHER): a randomized, open-
label, phase 2 trial
Abstract #LBA18
Mini Oral Session: Breast Cancer, Metastatic
Saturday, September 10
14:45 – 14:50 CEST
Retevmo
(selpercatinib)
Durable efficacy of selpercatinib in
patients (pts) with medullary thyroid
cancer (MTC): Update of the
LIBRETTO-001 trial
Abstract #1656P
Poster Session
Sunday, September 11
12:00 – 13:00 CEST
Retevmo
(selpercatinib)
Continuation of selpercatinib beyond
progression in RET fusion-positive
NSCLC: Data from LIBRETTO-001
study
Abstract #980P
Poster Session
Monday, September 12
12:00 – 13:00 CEST
